Enzo Biochem Inc
NYSE:ENZ
Relative Value
The Relative Value of one ENZ stock under the Base Case scenario is 1.6 USD. Compared to the current market price of 1.04 USD, Enzo Biochem Inc is Undervalued by 35%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Valuation Multiples
Multiples Across Competitors
ENZ Competitors Multiples
Enzo Biochem Inc Competitors
Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
---|---|---|---|---|---|---|---|---|
US |
Enzo Biochem Inc
NYSE:ENZ
|
52.5m USD | 0.8 | -11.5 | 0.1 | 0.1 | ||
US |
C
|
Cigna Group
XMUN:CGN
|
94.9B EUR | 0.5 | 19.8 | 10.2 | 13.6 | |
US |
Cigna Corp
NYSE:CI
|
99.9B USD | 0.5 | 19.3 | 10 | 13.3 | ||
US |
CVS Health Corp
NYSE:CVS
|
70B USD | 0.2 | 9.6 | 8.7 | 8.7 | ||
US |
Laboratory Corporation of America Holdings
NYSE:LH
|
17B USD | 1.4 | 39.2 | 11.9 | 18 | ||
DE |
F
|
Fresenius SE & Co KGaA
XETRA:FRE
|
15.7B EUR | 0.7 | -26.5 | 10.1 | 22.6 | |
US |
Quest Diagnostics Inc
NYSE:DGX
|
15.2B USD | 1.6 | 18.1 | 10.8 | 14.6 | ||
DE |
Fresenius Medical Care AG
XMUN:FME
|
11.9B EUR | 0.6 | 23.9 | 7 | 16.6 | ||
DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
11.5B EUR | 0.6 | 23.1 | 6.9 | 16.3 | |
US |
DaVita Inc
NYSE:DVA
|
11.9B USD | 1 | 17.3 | 8.4 | 12.4 | ||
US |
Oak Street Health Inc
NYSE:OSH
|
9.5B USD | 4.4 | -18.6 | -23.3 | -21.5 |